Table of Contents
Relevance: TGPSC: Telangana Economy, Industrial Development, Genome Valley, Life Sciences and Biotechnology.
For Prelims:
- NITI Aayog Trade Watch, Genome Valley, USFDA, Active Pharmaceutical Ingredient, Life Sciences
For Mains:
- Cluster-Based Development, Global Value Chains, Pharmaceutical Competitiveness, Export Diversification, Research and Innovation
Why in News?
NITI Aayog’s Trade Watch (January–March 2026) identified Telangana, Gujarat and Maharashtra as key pillars of India’s pharmaceutical industry.
Telangana is a leading centre for pharmaceutical manufacturing, life sciences, vaccines, biotechnology and exports. It contributes nearly 40% of India’s pharmaceutical production and hosts many globally approved manufacturing facilities.
What Does the NITI Aayog Report Highlight?
The report examined India’s trade performance during 2025–26 and identified pharmaceuticals as a sector with significant growth potential.
It noted that Telangana, Gujarat and Maharashtra collectively contribute substantially to:
- Pharmaceutical production
- Exports
- Research and development
- Vaccine manufacturing
- Active Pharmaceutical Ingredients
- Integration with global supply chains
The success of these States is based on manufacturing capacity, specialised industrial clusters, globally competitive firms and supportive policy ecosystems.
Why is Telangana a Major Pharmaceutical Hub?
Strong Manufacturing Base
- Telangana hosts more than 2,000 life-sciences companies, making it one of India’s largest pharmaceutical manufacturing centres.
Global Regulatory Compliance
- The State has more than 269 facilities approved by the United States Food and Drug Administration.
- USFDA-approved facilities indicate adherence to internationally accepted standards and help firms access major global markets.
Vaccine and Biotechnology Leadership
Telangana has emerged as a global hub for:
- Vaccines
- Life sciences
- Biotechnology
- Pharmaceutical research
- Advanced manufacturing
Supportive Policy Environment
The State’s pharmaceutical growth has been supported by:
- Industrial policies
- Research institutions
- Startup participation
- Infrastructure development
- Cluster-based planning
Together, these factors have enabled Telangana to become deeply integrated into global pharmaceutical value chains.
How Do Gujarat and Maharashtra Complement India’s Pharma Ecosystem?
Gujarat: Chemical and Export Strength
Gujarat has built its pharmaceutical industry on a strong chemical-manufacturing base.
Its major strengths include:
- Large number of manufacturing units
- Strong port connectivity
- Export orientation
- Chemical and pharmaceutical integration
- Backward linkages for raw materials
The State’s port access improves the movement of pharmaceutical products to international markets.
Maharashtra: Manufacturing and Research Capacity
Maharashtra combines large-scale pharmaceutical manufacturing with strong research and development capabilities.
Its strengths include:
- Large industrial base
- Globally compliant facilities
- Research institutions
- Skilled workforce
- Strong pharma clusters in the Mumbai–Pune corridor and other cities
The three States therefore perform complementary roles within India’s pharmaceutical ecosystem.
Why is the Pharmaceutical Sector Important to India?
India’s pharmaceutical industry has become a strategic pillar of the national economy.
Economic Contribution
The sector contributes:
- More than 1.7% of India’s GDP
- About 7.2% of manufacturing Gross Value Added
Employment
- The industry supports approximately 2.7 million livelihoods across manufacturing, research, distribution and allied activities.
Export Earnings
- Pharmaceutical and Active Pharmaceutical Ingredient exports together were valued at nearly $35.8 billion in 2025.
Global Healthcare Role
India is:
- One of the world’s largest suppliers of generic medicines
- A major producer of vaccines
- An important supplier of essential drugs
The sector therefore contributes to both India’s economy and global public health.
What Opportunities Does the Report Indicate?
Despite its large production base, India accounts for only around 2.8% of global pharmaceutical and API exports.
This indicates significant scope for expansion through:
Higher-Value Products
India can move beyond volume-based generic production towards:
- Complex generics
- Advanced vaccines
- Biotechnology products
- Innovative medicines
- Specialised APIs
Stronger Global Integration
- Regulatory compliance and reliable manufacturing can help Indian firms deepen their participation in global pharmaceutical supply chains.
Greater Research and Development
- Stronger linkages between firms, universities, research institutions and startups can improve product innovation.
Export Diversification
- India can expand its presence in new markets and reduce dependence on a limited number of destinations.
Expansion of Cluster-Based Growth
- The success of Genome Valley and other industrial clusters can guide the creation of similar integrated ecosystems.
Conclusion
Telangana’s strong manufacturing ecosystem, vaccine capabilities, USFDA-approved facilities and Genome Valley cluster have made it a central pillar of India’s pharmaceutical industry.
Along with Gujarat’s chemical and export strengths and Maharashtra’s manufacturing and research capabilities, Telangana is helping India deepen its integration into global pharmaceutical value chains.
The next stage of growth must focus on innovation, API self-reliance, global quality compliance, skilled manpower and sustainable manufacturing. This can help India move from being a major volume producer to a higher-value global pharmaceutical leader.
CARE MCQ
Q. Consider the following statements regarding India’s pharmaceutical industry:
- Telangana accounts for nearly 40% of India’s pharmaceutical production and hosts over 2,000 life sciences companies.
- Gujarat contributes around 33–40% of India’s pharmaceutical production, while Maharashtra accounts for about 14%.
Which of the statements given above is/are correct?
A. 1 only
B. 2 only
C. Both 1 and 2
D. Neither 1 nor 2
Answer: C
Explanation:
- Statement 1 is correct: Telangana contributes nearly 40% of India’s pharmaceutical production and has more than 2,000 life sciences companies, making it one of India’s leading pharmaceutical and biotechnology hubs.
- Statement 2 is correct: Gujarat contributes around 33–40% of India’s pharmaceutical production with over 3,000 manufacturing units, while Maharashtra contributes about 14% with over 3,800 units.
Additional Information
- Telangana has over 269 USFDA-approved manufacturing facilities and is a major global vaccine hub.
- Genome Valley (Hyderabad) is one of India’s premier life sciences and biotechnology clusters.
- According to NITI Aayog’s Trade Watch (January–March 2026), Telangana, Gujarat and Maharashtra are the three key pillars of India’s pharmaceutical industry.
FAQs
1. Which report recognised Telangana as a leading pharmaceutical hub?
The eighth edition of NITI Aayog’s Trade Watch report.
2. What share of India’s pharmaceutical production comes from Telangana?
Telangana accounts for nearly 40% of national pharmaceutical production.
3. What is Genome Valley?
It is a major life-sciences and biotechnology cluster in Telangana.
4. What is an API?
An Active Pharmaceutical Ingredient is the biologically active component used in manufacturing a medicine.
5. Why are USFDA-approved facilities important?
They indicate compliance with international manufacturing standards and facilitate access to regulated global markets.
6. What are Gujarat’s main pharmaceutical strengths?
Its chemical-pharma base, industrial clusters, export orientation and port connectivity.
7. What are Maharashtra’s major advantages?
Large-scale manufacturing, research capacity and strong industrial clusters.
8. What limits India’s future pharmaceutical growth?
Import dependence, limited global export share, research costs, regulatory compliance and the need for innovation.
